Supernus to Present at Two Investor Conferences in September

        Print
| Source: Supernus Pharmaceuticals, Inc.

ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in September 2013:

Rodman & Renshaw:
Presentation Date: Monday, September 9
Time: 11:40am ET
Place:  Millennium Broadway Hotel, NY
 
Stifel Nicolaus Weisel:
Presentation Date: Thursday, September 12
Time: 1:30pm ET
Place: Four Seasons Hotel, Boston, MA

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591